食品科学 ›› 2026, Vol. 47 ›› Issue (17): 190-203.doi: 10.7506/spkx1002-6630-20260131-285

• 营养卫生 • 上一篇    下一篇

富二十碳五烯酸-磷脂酰丝氨酸改善奥氮平诱导的小鼠肠道损伤

徐叶竹,梁岩岩,周亚峰,易文婷,许望龙,王怡涵,姜苏,唐云平   

  1. (1.浙江海洋大学食品与药学学院,浙江省海洋生物医用制品工程技术研究中心,浙江?舟山 316022;2.舟山市第二人民医院,浙江?舟山 316024;3.上海欧睿生物科技有限公司,上海 201101)
  • 出版日期:2026-09-15 发布日期:2026-09-03
  • 基金资助:
    舟山市卫生健康委员会医药卫生科技计划项目(2024YA10)

Ameliorative Effect and Underlying Mechanisms of Eicosapentaenoic Acid-Enriched Phosphatidylserine on Olanzapine-Induced Intestinal Injury in Mice

XU Yezhu, LIANG Yanyan, ZHOU Yafeng, YI Wenting, XU Wanglong, WANG Yihan, JIANG Su, TANG Yunping   

  1. (1. Zhejiang Provincial Engineering Technology Research Center of Marine Biomedical Products, Food and Pharmacy College, Zhejiang Ocean University, Zhoushan 316022, China; 2. Zhoushan Second People’s Hospital, Zhoushan 316024, China; 3. ECA Healthcare Inc., Shanghai 201101, China)
  • Online:2026-09-15 Published:2026-09-03

摘要: 目的:探究富二十碳五烯酸-磷脂酰丝氨酸(eicosapentaenoic acid-enriched phosphatidylserine,EPA-PS)对奥氮平(olanzapine,OLZ)诱导小鼠肠道损伤的改善作用及其机制。方法:将32 只雌性C57BL/6J小鼠随机分为正常组(CON组)、模型组(MOD组)、低剂量EPA-PS组(L-EPA-PS组,50 mg/kg)和高剂量EPA-PS组(H-EPA-PS组,100 mg/kg)。除CON组外,其余各组均采用8 mg/kg OLZ建立小鼠肠道损伤模型,连续灌胃给药42 d;同时,L-EPA-PS组和H-EPA-PS组分别给予相应剂量的EPA-PS。实验结束后,检测小鼠空肠组织炎症因子水平、氧化应激指标及紧密连接蛋白表达量,进行组织病理学分析,并对肠道内容物进行非靶向代谢组学和肠道菌群多样性分析。结果:与MOD组相比,EPA-PS可显著降低小鼠白细胞介素(interleukin,IL)-6、IL-1β、肿瘤坏死因子-α水平(P<0.05);显著增加分泌型免疫球蛋白A、超氧化物歧化酶、过氧化氢酶和谷胱甘肽过氧化物酶等活性(P<0.05),并显著降低丙二醛含量(P<0.05)。组织病理学和免疫荧光分析显示,EPA-PS改善了空肠组织结构并显著上调了相关紧密连接蛋白水平(P<0.05)。肠道内容物非靶向代谢组学分析显示,EPA-PS可通过调节色氨酸代谢、鞘脂代谢和花生四烯酸代谢缓解OLZ导致的肠道代谢紊乱。另外,肠道菌群多样性分析表明,EPA-PS可通过调节Bacteroidota、norank_f__Muribaculaceae、Bifidobacterium、Faecalibaculum、Turicibacter、Dubosiella等菌属缓解OLZ导致的小鼠肠道菌群紊乱。结论:EPA-PS可在一定程度上改善OLZ诱导的小鼠肠道损伤,其作用可能与调控炎症反应和氧化应激、调节肠道菌群结构及改善肠道代谢紊乱有关。

关键词: 奥氮平;富二十碳五烯酸-磷脂酰丝氨酸;肠道损伤;代谢组学;肠道菌群

Abstract: Objective: To investigate the alleviating effects and underlying mechanisms of eicosapentaenoic acid-enriched phosphatidylserine (EPA-PS) on olanzapine (OLZ)-induced intestinal injury in mice. Methods: Thirty-two female C57BL/6J mice were randomly divided into a control group (CON), a model group (MOD), a low-dose EPA-PS group (L-EPA-PS, 50 mg/kg), and a high-dose EPA-PS group (H-EPA-PS, 100 mg/kg). To induce intestinal injury, all mice except those in the CON group were orally administered with OLZ at a dose of 8 mg/kg for 42 consecutive days. Meanwhile, mice in the L-EPA-PS and H-EPA-PS groups received the corresponding doses of EPA-PS. At the end of the experiment, inflammatory cytokine levels, oxidative stress indicators, and tight junction protein expression in jejunal tissues were measured. Histopathological analysis was performed, and untargeted metabolomics and microbiota diversity analyses were conducted on intestinal contents. Results: Compared with the MOD group, EPA-PS intervention significantly reduced the levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α) in mice (P < 0.05). EPA-PS also significantly increased the level of secretory immunoglobulin A (sIgA) and the activities of antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase (P < 0.05), while significantly decreasing malondialdehyde (MDA) levels (P < 0.05). Histopathological and immunofluorescence analyses showed that EPA-PS improved jejunal tissue structure and significantly up-regulated the expression of related tight junction proteins (P < 0.05). Untargeted metabolomics analysis of intestinal contents indicated that EPA-PS alleviated OLZ-induced intestinal metabolic disturbances by regulating tryptophan, sphingolipid, and arachidonic acid metabolism. In addition, gut microbiota diversity analysis demonstrated that EPA-PS ameliorated OLZ-induced gut microbiota dysbiosis by modulating the abundance of Bacteroidota, norank_f__Muribaculaceae, Bifidobacterium, Faecalibaculum, Turicibacter, and Dubosiella. Conclusion: EPA-PS may alleviate OLZ-induced intestinal injury in mice, potentially through the regulation of inflammatory responses and oxidative stress, the modulation of gut microbiota structure, and the amelioration of intestinal metabolic disturbances

Key words: olanzapine; eicosapentaenoic acid-enriched phosphatidylserine; intestinal injury; metabolomics; gut microbiota

中图分类号: